Activity of T-DM1 in Her2-positive breast cancer brain metastases. - Wikidata - awgldk - TriplyDB

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

http://www.wikidata.org/entity/Q41455800

about

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases.ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A CASE SERIES.Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Updates in the management of brain metastases.Brain metastasis: Unique challenges and open opportunities.Targeted Treatment of Brain Metastases.Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review.Targeted therapy of brain metastases: latest evidence and clinical implications.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.Mechanisms and Therapy for Cancer Metastasis to the Brain.Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours†

P2860

Q26746081-11C3A6A3-E6B2-4925-A871-D7F6BF230822 Q33867316-904C7B57-88B2-4C29-BFB0-B623C2EB4D50 Q36067578-8B1BDF0B-67C6-4234-A825-40E41CBCB775 Q36825346-AB54A989-6448-460B-97CE-553FE3FF3657 Q37653981-76ABEB3A-C3F6-4C7B-B279-2A90871773E7 Q38611899-615613FD-79B8-4013-BE2B-2A7C99106BFB Q38829087-86AC3874-D97C-4D65-80D4-1119661C2908 Q38887451-86EC6982-CD45-446D-8C24-C134381DCD34 Q39035128-AD3542A0-6226-4A7B-957C-5A29D38AF6BB Q39192200-097E45BD-4003-4517-8BA0-7F350C310458 Q39229266-40DF599A-9865-46E9-B106-D769669D9597 Q44844636-549D1785-3F5E-475F-BDC9-A6C7A963B376 Q47839509-215947B3-C267-438F-A9E9-E6A729D96B8F Q48162978-0B37D01B-8BB8-4641-A028-3AC06AE8779F Q49956245-12E134AC-7317-4689-A901-5318D166BE3D Q54118354-3F8C4A9C-A193-428E-991C-CEC3A500E381 Q54950354-2F431BB5-C8C7-4765-82A0-A9F4B4EEE25D Q54962187-90FCD2EE-C151-42B7-9CF2-1088DB5D312B Q57578829-C36BB77A-303E-4946-8B01-025FD11D55FA

P2860

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

http://www.wikidata.org/entity/Q41455800

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

@en

type

label

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

@en

prefLabel

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

@en

P1433

Q41455800-ABB2353F-F272-48DC-96F9-D9630D67F332

P1476

Q41455800-4DC8C393-BCC2-4635-9D79-7A8E547D1FDE

P2093

Q41455800-08273F69-031D-463A-B7E6-C2B7990771E3

Q41455800-1E968294-5256-444A-9A8D-7BE957BFEB35

Q41455800-30400326-4545-412D-BF98-930BFDDF1737

Q41455800-5815234D-EE80-4274-9F71-57BD1C701AA2

Q41455800-886C38BB-574A-47C6-8890-C58651DF51E8

Q41455800-8E23D3BF-0C45-4894-8224-C02B7183933B

Q41455800-8FD6F3B6-958D-4360-9BA3-A48FECA037CD

Q41455800-B2C7838B-4694-4261-A25A-F77CA8E031F3

Q41455800-BF6A6AE2-17B8-4E32-B5BC-809069D7E793

Q41455800-CEC65BE3-439D-435D-BB3C-3D26729DEE69

P2860

Q41455800-0719BC2E-105D-4CD5-B8F7-6F056E9A3A65

Q41455800-086FAA0F-7011-47A9-97BA-13F7B31A02FA

Q41455800-3BCEFDDD-54B9-4930-9891-45362FBF0B05

Q41455800-461C8EB9-8D9E-4F0B-A81D-D0376EDB09F4

Q41455800-5CDDA61C-2DE5-42ED-BA1E-6A5E8A0E60F7

Q41455800-7711F914-1BEC-4D47-BC03-C49DA96EC2EE

Q41455800-7D89DE14-AE54-417D-ADB7-C9DC30A8BECA

Q41455800-7EBE4D37-016A-4C34-8F06-BB188BAA5DA0

Q41455800-8DE78901-8200-47EB-B64C-CD9D46DD0BBF

Q41455800-97D31407-FD7C-40E1-8774-F5AF0A388011

P2888

Q41455800-C01AF8AE-2090-489D-9CA1-1F365804C63B

P304

Q41455800-DAF5B8CB-B8C1-4C00-B18E-1F279F605234

P31

Q41455800-27253286-19B3-4321-97B7-8D7B6BEB1130

P356

Q41455800-9DFA5561-F214-480E-9481-39F9E78A3AA5

P433

Q41455800-A79F7B72-0DA6-4D3E-9622-82F82C726FD9

P478

Q41455800-6D8EEA25-1B2E-4844-89FA-C662DD5F7A58

P50

Q41455800-407B7257-EC34-4F26-8D4B-2108E79B0820

Q41455800-CEA3E179-BC5C-4B12-A6DD-2189A76E9D89

P577

Q41455800-B2480512-D3C7-4755-A9EC-AB8E434C7ADB

P6179

Q41455800-27B771DE-8412-492F-B372-C3A56F0408BC

P698

Q41455800-384F6544-6993-44EC-BBB8-E6529749711A

P356

S10585-015-9740-3

P1433

Clinical & Experimental Metastasis

P1476

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

@en

P2093

Arik Galid

http://www.w3.org/2001/XMLSchema#string

Christoph C Zielinski

http://www.w3.org/2001/XMLSchema#string

Elisabeth Bergen

http://www.w3.org/2001/XMLSchema#string

Guenther G Steger

http://www.w3.org/2001/XMLSchema#string

Karin Dieckmann

http://www.w3.org/2001/XMLSchema#string

Katja Pinker

http://www.w3.org/2001/XMLSchema#string

Leopold Oehler

http://www.w3.org/2001/XMLSchema#string

Margaretha Rudas

http://www.w3.org/2001/XMLSchema#string

Michael Gnant

http://www.w3.org/2001/XMLSchema#string

Peter Dubsky

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab emtansine for HER2-positive advanced breast cancer.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Response assessment criteria for brain metastases: proposal from the RANO group.

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis.

Breast cancer metastasis to the central nervous system

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

P2888

s10585-015-9740-3

P304

729-737

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10585-015-9740-3

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Preusser

Anna S Berghoff

P577

2015-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007579842

http://www.w3.org/2001/XMLSchema#string

P698

26303828

http://www.w3.org/2001/XMLSchema#string